Thalia Therapeutics: The Drug Could Work

Thalia Therapeutics (LSE:THAT) has signed a Clinical Trial Agreement, a decisive step forward in advancing a treatment for Leukaemia. The Company is developing innovative RNA-based therapeutics and delivery technologies across oncology and cardiovascular disease. An agreement with City of Hope, one of the world’s leading cancers research and treatment centres supports completion of Phase 1 […]
The post Thalia Therapeutics: The Drug Could Work appeared first on UK Investor Magazine.
